ENHANCE (Elevated NKG2A and HLA-E Amplify NK/CD8 Checkpoint Engagers): A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Status: Open to Accrual

Learn more: 

• https://clinicaltrials.gov/study/NCT06503614

Study Contact: studies@hoosiercancer.org; (317) 921-2050.